About

Built by people who have done each layer.

QRGenAI sits where structural chemistry, molecular genetics, neuroscience and machine learning meet. Every one of those layers is held in-house by someone who has done it at research level.

Leadership

Backed by proven leaders. Validated by world-class clinicians.

Chief Executive Officer

Moshit Yaffe

Entrepreneur and operator. Founded and ran her own boutique investment banking firm, raising $70M+ for 15+ companies, and took a company through IPO and merger as CEO. Board-qualified attorney. Drives QRG’s strategy, capital and pharma partnerships.

Co-Founder & CTO

Dr. Shane Wald-Altman

Ph.D. and postdoctoral research at Tel Aviv University. She built QR Genetics’ AI-driven drug discovery platform in its entirety and leads the company’s scientific and technology strategy. Inventor on multiple patent applications; the platform has generated several therapeutic assets now advancing toward clinical validation.

VP R&D

Dr. Noa Bielopolski

PhD in neuroscience, Tel Aviv University, following an MSc in neuroscience and a dual-major BSc in neuroscience, psychology and biology, all at Tel Aviv University. Leads R&D.

Advisors

Senior pharma leadership. World-class science.

Co-Founder & Scientific Advisor

Prof. Miguel Weil

Associate Professor, Dept. of Cell Research & Immunology, Tel Aviv University. Founder and Director of the Cell Screening Facility for Personalized Medicine, Israel’s first fully automated high-content drug-screening facility for rare disease. PhD, Hebrew University; EMBO postdoctoral fellow, University College London. Joint last author on the ACTA2 first-in-human paper.

Chairman

Avinoam Sapir

Investor and business leader with 25 years in pharma across a series of senior chief-executive roles: CEO of SLE, CEO of Teva Israel, CEO of Tikun Olam, and Regional Director for the Middle East. Chairman of Sanara Ventures, and today chairman of a pharmaceutical import company.

Scientific Advisory Board in formation, to be announced shortly.

The team

A multidisciplinary team across biology and AI.

Beyond the leadership team, QR Genetics is built by doctorate-level scientists and engineers, with PhDs spanning computational chemistry, molecular genetics, neuroscience and computer science, alongside degrees in medicinal chemistry and biomedical engineering.

Structural & computational chemistry

The molecular-dynamics and virtual-screening depth that QRGenAI’s four-dimensional modelling rests on.

Molecular genetics & neuroscience

The biology that turns a structural prediction into a testable disease mechanism.

AI & engineering

Doctoral AI research and published work on machine learning for molecular property prediction.

Trained atTel Aviv UniversityTechnionWeizmann Institute of ScienceJohns Hopkins University

Selected publications

Peer-reviewed work.

Re-Purposing Sapropterin (Kuvan) for ACTA2-Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First-In-Human Therapeutic Report. Hausman-Kedem, Bielopolski, Krishnan, Wald-Altman, Shrian, Bar-Yosef, Kapusta, Shamber, Musolino, Weil. Annals of Clinical & Translational Neurology, 2026.Open access · doi.org/10.1002/acn3.70493

Functional signatures of de novo GABBR1 and GABBR2 variants associated with neurodevelopmental disorders. Stawarski, Bielopolski, Roitman, Fridman, Wald-Altman, Antonarakis, Gassmann, Bettler et al. npj Genomic Medicine, 2026.doi.org/10.1038/s41525-026-00558-z

Characterization of a de novo GABBR2 variant linked to autism spectrum disorder. Bielopolski, Stawarski, Roitman, Fridman, Wald-Altman, Früh, Bettler, Nissenkorn. Frontiers in Molecular Neuroscience 16:1267343, 2023.doi.org/10.3389/fnmol.2023.1267343

“Virtual patch clamp analysis” for predicting the functional significance of pathogenic variants in sodium channels. Bielopolski, Heyman, Bassan, Ben-Zeev, Tzadok, Lerman-Sagie, Wald-Altman, Nissenkorn et al. Epilepsy Research 186:107002, 2022.doi.org/10.1016/j.eplepsyres.2022.107002

Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1(G93A) mouse model. Lilo, Wald-Altman, Solmesky, Ben Yaakov, Gershoni-Emek, Perlson, Weil et al. Human Molecular Genetics 22(23):4720-5, 2013.doi.org/10.1093/hmg/ddt325

Collaborators

Where the work is done.

Academic

Yale · Harvard / Mass General Hospital · Tel Aviv University

Clinical sites

Sheba · Wolfson · Tel Aviv Sourasky (Ichilov)

Technology

Google · NVIDIA Inception · Microsoft for Startups · Meta accelerator alumnus